In addition, several studies showed that SGLT2-is reduce the risk of new-onset AF and the incidence of intracardiac thrombosis, which sets a new direction for the use of SGLT2-is in ACM [173,174,175]. Here, SLC5A2 is linked to atrial fibrillation.